We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Suggests Conditional Approval for Lilly Imaging Agent
FDA Panel Suggests Conditional Approval for Lilly Imaging Agent
January 28, 2011
An FDA advisory committee said an Eli Lilly contrast agent that may be useful in predicting Alzheimer’s disease could be approved if the company conducts physician training to make sure brain scans are read consistently.